# PembROlizuMab Immunotherapy Versus Standard Chemotherapy for Advanced prE-treated Malignant Pleural Mesothelioma

> **NCT02991482** · PHASE3 · COMPLETED · sponsor: **ETOP IBCSG Partners Foundation** · enrollment: 144 (actual)

## Conditions studied

- Pleural Mesothelioma Malignant Advanced

## Interventions

- **DRUG:** Pembrolizumab
- **DRUG:** Gemcitabine
- **DRUG:** Vinorelbine

## Key facts

- **NCT ID:** NCT02991482
- **Lead sponsor:** ETOP IBCSG Partners Foundation
- **Sponsor class:** NETWORK
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-09-12
- **Primary completion:** 2019-02-20
- **Final completion:** 2021-11-30
- **Target enrollment:** 144 (ACTUAL)
- **Last updated:** 2022-08-24

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02991482

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02991482, "PembROlizuMab Immunotherapy Versus Standard Chemotherapy for Advanced prE-treated Malignant Pleural Mesothelioma". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT02991482. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*